Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum — an adjuvant to antiretroviral tritherapy

doi:10.1016/S0753-3322(99)80065-1

Biomedicine & Pharmacotherapy

Volume 53, Issue 2, March 1999, Pages 90-92

https://doi.org/10.1016/S0753-3322(99)80065-1 Get rights and content

Summary

HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However, since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV-1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFNα vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFNα Abs (whether under HAART or not) when compared to placebo or non-responder vaccinees, a strong correlation was found between an increased IFNα neutralizing capacity and the reduction ot clinical manifestations.

References (8)

FinziD et al.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Science
(1997)
ChunTW et al.
Early establishment of a pool of latently infected, resting CD4⁺ T cells during primary HIV-1 infection
ZaguryJF et al.
Model of AIDS immunopathogenesis based on the HIV-1 gp120 and Tat-induced dysregulation of uninfected immune cells
AIDS Sci
(1996)
ZaguryD et al.
Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS

There are more references available in the full text version of this article.

Cited by (15)

Characterization and potential clinical applications of autoantibodies against cytokines
2009, Cytokine and Growth Factor Reviews
Autoantibodies recognizing cytokines arise in certain patients during the course of therapy with recombinant cytokines, although they may arise spontaneously as well. They are typically high avidity and in vitro neutralizing IgG antibodies present in picomolar to nanomolar concentrations. Methodology is therefore critical. Quantitative studies based on sound methodology strongly indicate that nanomolar levels of cytokine autoantibodies are likely to be involved in a number of “new” syndromes such as acquired immune deficiencies, lung diseases, and certain age-related manifestations. There are many ways in which the autoantibodies could be naturally induced, and they have been experimentally induced with ease. Therefore, a new therapeutic concept of inducing cytokine autoantibodies via anti-cytokine vaccination is currently rapidly emerging.
Active immunization against murine TNFα peptides in mice: Generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection
2004, Vaccine
New lines of treatment targeting cytokines have been successfully developed recently and are now widely used in therapy. They are based on passive administration of cytokine inhibitors either soluble receptors or mAbs and the major example is TNFα in rheumatoid arthritis (RA). Since a few years, our group has developed a novel alternative approach targeting cytokines by using active immunization against biologically inactive but immunogenic cytokine derivatives. In the present work, we present a new aspect of this research, based on immunization against specific cytokine peptides chosen by molecular modelling. We could elicit a significant humoral response against four TNFα peptides by active immunization, and show that the Abs generated cross-reacted with the native cytokine with good titers as determined by ELISA. Interestingly, during coimmunization experiments with couples of peptides, one showed a clear immunodominant effect over the other.
Overall, we could not show the neutralization of TNFα biological activity in vitro by the immunized sera, but it seems that it is not a prerequisite to observe clinical efficacy. Indeed, using the LPS/galactosamine-induced shock, we could demonstrate that one of the four peptides tested conferred a clinical protection.
These results validate the feasibility and efficacy of active immunization against cytokine peptides, and confirm that active immunization against cytokines could represent in the future an alternative to passive immunization in many diseases.
Multiple Homozygous Variants in the STING-Encoding TMEM173 Gene in HIV Long-Term Nonprogressors
2018, Journal of Immunology
Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infection
2014, Current HIV Research
Attenuation of CCl<inf>4</inf>-induced hepatic fibrosis in mice by vaccinating against TGF-β1
2013, PLoS ONE
Vaccination with platelet-derived growth factor B kinoids inhibits CCl <inf>4</inf>-induced hepatic fibrosis in mice
2012, Journal of Pharmacology and Experimental Therapeutics

View all citing articles on Scopus

View full text

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum — an adjuvant to antiretroviral tritherapy

Summary

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Science

Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection

Model of AIDS immunopathogenesis based on the HIV-1 gp120 and Tat-induced dysregulation of uninfected immune cells

AIDS Sci

Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS

Early establishment of a pool of latently infected, resting CD4⁺ T cells during primary HIV-1 infection